Moscow, May 7, 2013 — Pharmstandard OJSC (LSE: PHST LI, MICEX-RTS: PHST RU) («Pharmstandard» or/and the «Company») announces that pursuant to the Company’s buyback program, announced on February 15, 2013 (further the «Program»), 3,276,305 GDRs were purchased on the open market as of May 6, 2013.
All purchases of GDRs were made by an independent broker Citigroup Global Markets Limited for the account of Pharmstandard-Leksredstva OJSC, an indirect wholly owned subsidiary of the Company.
Therefore, since the start of Pharmstandard’s buyback program the securities at the total amount of approximately RUR 2.1 billion have been purchased.
The Program was approved in respect of ordinary shares of Pharmstandard OJSC and/or Global Depositary Receipts representing Shares (each Share representing 4 GDRs) in the aggregate amount of up to RUR8 billion. Duration of program: December 31, 2013
New shareholder structure is as follows:
Augment Investments Limited — 54.32% (ordinary shares and GDRs)
LSE — 25.39% (GDRs)
RTS/MICEX — 9.68% (ordinary shares)
Pharmstandard-Leksredstva OJSC — 10.61% (ordinary shares and GDRs)
Tel. (495) 970–0030 ext.2824
Fax (495) 970–0032